Anixa Biosciences treats second patient in cohort 5 of Phase 1 ovarian cancer CAR-T trial
Bitget2026/10/01 12:35- Anixa treated a second patient in cohort 5 of its Phase 1 FSHR-targeted CAR-T trial for recurrent ovarian cancer.
- Results have not been presented; the update centers on enrollment progress and interim observations from the ongoing study.
- Management cited multiple patients living beyond one year post-treatment, including one beyond two years, in a heavily pre-treated population.
- No dose-limiting toxicities have been observed so far across cohorts, including the first patient treated at the highest dose level.
- The read-through supports continued dose escalation and could shape partnering interest for a solid-tumor CAR-T program.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Dollar Index slips from its 18-month high
Monnalisa shares delist from Euronext Growth Milan
Monnalisa’s delisting from trading on Euronext Growth Milan took effect today. The company is preparing a shareholder buyback process led by Modamet and Jafin Due for investors seeking to sell. Further details are due in coming days on the purchase window and a single settlement date for the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monnalisa S.p.A. published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
ICE brings futures trading to London’s $190 billion-a-day physical gold market
Precia reports 5,733,040 issued shares, 8,350,574 exercisable voting rights as of Aug. 31, 2026
Precia disclosed 5,733,040 issued shares as of Aug. 31, 2026. Theoretical voting rights totaled 8,677,204. Exercisable voting rights stood at 8,350,574, reflecting 326,630 treasury shares without voting rights. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precia SA published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
